Drugs in Dev.
Pulmonary/Respiratory Diseases
Undisclosed
Switzerland 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lonodelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : CSHL
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 27, 2020
Lead Product(s) : Lonodelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : CSHL
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NI-0101
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Edesa Biotech
Deal Size : $372.0 million
Deal Type : Licensing Agreement
Details : The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : NI-0101
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Edesa Biotech
Deal Size : $372.0 million
Deal Type : Licensing Agreement
